Analyst Price Targets — SNDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 27, 2026 5:03 pm | Stephen Willey | Stifel Nicolaus | $45.00 | $21.71 | StreetInsider | Syndax Pharmaceuticals (SNDX) PT Raised to $45 at Stifel |
| November 24, 2025 11:31 am | — | Barclays | $35.00 | $17.44 | TheFly | Syndax price target raised to $35 from $22 at Barclays |
| November 4, 2025 12:36 pm | — | UBS | $38.00 | $13.76 | TheFly | Syndax price target raised to $38 from $35 at UBS |
| November 4, 2025 10:09 am | Peter Lawson | Barclays | $22.00 | $13.76 | TheFly | Syndax price target raised to $22 from $19 at Barclays |
| September 10, 2025 9:10 am | — | Stifel Nicolaus | $44.00 | $15.73 | TheFly | Syndax resumed with a Buy at Stifel |
| July 15, 2025 10:51 am | David Dai | UBS | $35.00 | $9.80 | TheFly | Syndax price target lowered to $35 from $37 at UBS |
| July 10, 2025 8:56 am | Corinne Johnson | Goldman Sachs | $18.00 | $9.82 | TheFly | Syndax initiated with a Buy at Goldman Sachs |
| November 13, 2024 12:18 pm | George Farmer | Scotiabank | $18.00 | $20.04 | StreetInsider | Syndax Pharmaceuticals (SNDX) PT Lowered to $18 at Scotiabank |
| October 24, 2024 3:22 am | David Dai | UBS | $37.00 | $18.54 | StreetInsider | UBS Starts Syndax Pharmaceuticals (SNDX) at Buy |
| August 15, 2024 9:27 am | Yigal Nochomovitz | Citigroup | $34.00 | $20.09 | StreetInsider | Syndax Pharmaceuticals (SNDX) PT Raised to $34 at Citi |
Latest News for SNDX
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $1.1 per share a year ago.
– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr) net revenue of $56.0 million in 4Q25, a 22% increase vs 3Q25, and $151.6 million in FY2025, resulting in Syndax collaboration revenue of $42.4 million in FY2025 – – Completed enrollment in Phase 2…
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference in Boston, MA, with a…
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, February 26, 2026. In connection with the earnings release, Syndax's management will host a conference call and live…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SNDX.
U.S. House Trading
No House trades found for SNDX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.